Drug intelligence / Profile preview

SBM-05

Development stage: Unknown
Lead developer: Shilpa Biologicals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SBM-05 is a biosimilar monoclonal antibody developed by Shilpa Biologicals that targets the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, SBM-05 prevents its interaction with ligands PD-L1 and PD-L2, thereby inhibiting the immunosuppressive signaling pathway that tumors use to evade the immune system. This blockade enhances T-cell-mediated antitumor activity. SBM-05 is currently being developed for the treatment of various malignancies, including melanoma, Hodgkin disease, renal cell carcinoma, and non-small cell lung carcinoma, and is in Phase 1 clinical development.

Other names: pembrolizumab biosimilarMonoclonal Antibodies Biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on SBM-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBM-05.

Explore the full profile